Trials / Completed
CompletedNCT00310492
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis
Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | subcutaneous immunotherapy | Updosing by 16 injections to 100,000 SQ-U |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2009-05-01
- Completion
- 2009-11-01
- First posted
- 2006-04-04
- Last updated
- 2015-12-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00310492. Inclusion in this directory is not an endorsement.